


## (2S,3R)-Voruciclib

<b>Cat. No.:</b>	HY-12422C
<b>CAS No.:</b>	1253731-24-6
<b>Molecular Formula:</b>	C <sub>22</sub> H <sub>19</sub> ClF <sub>3</sub> NO <sub>5</sub>
<b>Molecular Weight:</b>	469.84
<b>Target:</b>	CDK
<b>Pathway:</b>	Cell Cycle/DNA Damage
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	(2S,3R)-Voruciclib is the (2S,3R)-enantiomer of Voruciclib. (2S,3R)-Voruciclib is an orally active CDK inhibitor <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	CDK <sup>[1]</sup>
<b>In Vitro</b>	(2S,3R)-Voruciclib (Compound B, formula I) is used in combination with a compound capable of inhibiting EGFR kinase activity and Gemcitabine to treat pancreatic cancer <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Veena Agarwal, et al. A synergistic pharmaceutical combination for the treatment of pancreatic cancer. WO2012123889A1.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA